UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 386

Sortiert nach

RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients

Pathology oncology research, 2023-04, Vol.29, p.1611138-1611138

2023

Volltextzugriff (PDF)

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2018-01, Vol.13 (1), p.27-45

2018

Volltextzugriff (PDF)

Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population

Mutation research, 2006-07, Vol.599 (1), p.26-35

2006

Volltextzugriff (PDF)

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer

Future oncology (London, England), 2021-03, Vol.17 (7), p.763-773

2021

Volltextzugriff (PDF)

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.1595-1601

2018

Volltextzugriff (PDF)

Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC

Journal of thoracic oncology, 2020-12, Vol.15 (12), p.1928-1934

2020

Volltextzugriff (PDF)

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

Annals of oncology, 2017-02, Vol.28 (2), p.292-297

2017

Volltextzugriff (PDF)

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape

The oncologist (Dayton, Ohio), 2023-05, Vol.28 (5), p.402-413

2023

Volltextzugriff (PDF)

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

Annals of oncology, 2016-07, Vol.27 (7), p.1286-1291

2016

Volltextzugriff (PDF)

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma

Frontiers in oncology, 2022-12, Vol.12, p.1042525

2022

Volltextzugriff (PDF)

Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study

Clinical lung cancer, 2020-09, Vol.21 (5), p.e349-e354

2020

Volltextzugriff (PDF)

Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)

Lung cancer (Amsterdam, Netherlands), 2022-12, Vol.174, p.118-124

2022

Volltextzugriff (PDF)

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI

Lung cancer (Amsterdam, Netherlands), 2015-09, Vol.89 (3), p.357-359

2015

Volltextzugriff (PDF)

Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice

Japanese journal of clinical oncology, 2020-05, Vol.50 (5), p.594-601

2020

Volltextzugriff (PDF)

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients

Journal of thoracic oncology, 2016-01, Vol.11 (1), p.122-127

2016

Volltextzugriff (PDF)

Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

Cancer Research and Treatment, 2023, 55(4), , pp.1144-1151

2023

Volltextzugriff (PDF)

LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer

Future oncology (London, England), 2022-09, Vol.18 (28), p.3133-3141

2022

Volltextzugriff (PDF)

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)

Translational lung cancer research, 2021-01, Vol.10 (1), p.314-325

2021

Volltextzugriff (PDF)

Genetic alterations in the RAS/RAF/mitogen‐activated protein kinase and phosphatidylinositol 3‐kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma

Cancer, 2010-06, Vol.116 (12), p.2974-2983

2010

Volltextzugriff (PDF)

Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer

Anti-cancer drugs, 2024-07, Vol.35 (6), p.559

2024

Volltextzugriff (PDF)

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Journal of translational medicine, 2022-09, Vol.20 (1), p.1-390, Article 390

2022

Volltextzugriff (PDF)

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study

Journal of hematology and oncology, 2020-04, Vol.13 (1), p.37-12, Article 37

2020

Volltextzugriff (PDF)

Intraductal Carcinoma of Salivary Glands Harboring TRIM27-RET Fusion with Mixed Low Grade and Apocrine Types

Head & neck pathology (Totowa, N.J.), 2020-03, Vol.14 (1), p.239-245

2020

Volltextzugriff (PDF)

Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients

Oncology research, 2019-05, Vol.27 (5), p.575-582

2019

Volltextzugriff (PDF)

Combined Dacomitinib and Selpercatinib Treatment for a Patient with EGFR-Mutant Non-Small Cell Lung Cancer and Acquired CCDC6-RET Fusion

OncoTargets and therapy, 2024-06, Vol.17, p.499-506

2024

Volltextzugriff (PDF)

1 – 25 von 386

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(344)
Mit Volltextzugriff
(319)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(323)
Science & Technology
(314)
Life Sciences & Biomedicine
(307)
Gene Rearrangement
(247)
Thyroid Neoplasms - Genetics
(214)
Proto-Oncogene Proteins C-Ret - Genetics
(166)
Female
(165)
Male
(149)
Oncology
(149)
Carcinoma, Papillary - Genetics
(128)
Adult
(122)
Middle Aged
(117)
Proto-Oncogene Proteins - Genetics
(112)
Mutation
(110)
Thyroid Neoplasms - Pathology
(109)
Proto-Oncogene Proteins C-Ret
(102)
Receptor Protein-Tyrosine Kinases - Genetics
(102)
Biological And Medical Sciences
(101)
Aged
(97)
Medical Sciences
(85)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Oncogene
(23)
Thyroid
(21)
The Journal Of Clinical Endocrinology And Metabolism
(15)
The American Journal Of Surgical Pathology
(11)
Lung Cancer
(10)
Cancer Research
(9)
Histopathology
(9)
Cancer
(7)
Clinical Cancer Research
(7)
Cancer Letters
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer

Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers

Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma

Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study

Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI

Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients

Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)

Genetic alterations in the RAS/RAF/mitogen‐activated protein kinase and phosphatidylinositol 3‐kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma

Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study

Intraductal Carcinoma of Salivary Glands Harboring TRIM27-RET Fusion with Mixed Low Grade and Apocrine Types

Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients

Combined Dacomitinib and Selpercatinib Treatment for a Patient with EGFR-Mutant Non-Small Cell Lung Cancer and Acquired CCDC6-RET Fusion

Suchergebnisse filtern